Journal of Surgery Concepts & Practice >

2025 , Vol. 30 >Issue 06: 474 - 478

DOI: https://doi.org/10.16139/j.1007-9610.2025.06.03

Experts forum

Reflections on key issues in neoadjuvant therapy for pancreatic cancer: a paradigm shift from evidence-based medicine to precision medicine

  • KANG Xiaochao ,
  • LI Yikai ,
  • GUO Shiwei ,
  • JIN Gang
Expand
  • Department of Hepatobiliary Pancreatic Spleen Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China

Received date: 2025-06-27

  Online published: 2026-01-26

Fold

Abstract

Neoadjuvant therapy for pancreatic cancer is undergoing a paradigm shift from conventional chemotherapy to precision medicine. This expert forum discussed cutting-edge issues in pancreatic cancer neoadjuvant therapy from an evidence-based perspective, incorporating the latest clinical research advances. We focused on innovative directions including immunotherapy combination strategies, liquid biopsy applications, artificial intelligence (AI)-assisted decision making, and individualized precision medicine. We proposed forward-looking concepts such as molecular subtyping-guided individualized treatment strategies, multi-omics integrated efficacy prediction models, and standardized multidisciplinary collaborative care systems. These innovative concepts will drive pancreatic cancer neoadjuvant therapy toward more precise and effective directions.

Key words： Pancreatic cancer; Neoadjuvant therapy; Precision medicine; Immunotherapy; Liquid biopsy; Artificial intelligence（AI）

Cite this article

KANG Xiaochao , LI Yikai , GUO Shiwei , JIN Gang . Reflections on key issues in neoadjuvant therapy for pancreatic cancer: a paradigm shift from evidence-based medicine to precision medicine[J]. Journal of Surgery Concepts & Practice, 2025 , 30(06) : 474 -478 . DOI: 10.16139/j.1007-9610.2025.06.03

References

[1] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263.
[2] STOFFEL E M, BRAND R E, GOGGINS M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention[J]. Gastroenterology, 2023, 164(5):752-765.
[3] STROBEL O, NEOPTOLEMOS J, J?GER D, et al. Optimizing the outcomes of pancreatic cancer surgery[J]. Nat Rev Clin Oncol, 2019, 16(1):11-26.
[4] WU M Y, SHEN M, XU M D, et al. FOLFIRINOX regulated tumor immune microenvironment to extend the survival of patients with resectable pancreatic ductal adenocarcinoma[J]. Gland Surg, 2020, 9(6):2125-2135.
[5] DAI G H, RU J, SI H Y, et al. A phase 1b/2 study of surufatinib plus camrelizumab,nab-paclitaxel,and S-1(NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma(mPDAC)[J]. J Clin Oncol, 2023, 41(16):4142.
[6] RENOUF D J, LOREE J M, KNOX J J, et al. The CCTG PA.7 phase Ⅱ trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma[J]. Nat Commun, 2022, 13(1):5020.
[7] PADRóN L J, MAURER D M, O’HARA M H, et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial[J]. Nat Med, 2022, 28(6):1167-1177.
[8] KIRCHHAMMER N, TREFNY M P, AUF DER MAUR P, et al. Combination cancer immunotherapies: emerging treatment strategies adapted to the tumor microenvironment[J]. Sci Transl Med, 2022, 14(670):eabo3605.
[9] GALON J, BRUNI D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies[J]. Nat Rev Drug Discov, 2019, 18(3):197-218.
[10] KRUGER S, HEINEMANN V, ROSS C, et al. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer[J]. Ann Oncol, 2018, 29(12):2348-2355.
[11] WATANABE F, SUZUKI K, AIZAWA H, et al. Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging[J]. Sci Rep, 2023, 13(1):4809.
[12] DU J, LU C, MAO L, et al. PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC/LAPC: a biomolecular exploratory, phase Ⅱ trial[J]. Cell Rep Med, 2023, 4(3):100972.
[13] GEMENETZIS G, GROOT V P, YU J, et al. Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status: results of the prospective cluster study[J]. Ann Surg, 2018, 268(3):408-420.
[14] NASIEF H, ZHENG C, SCHOTT D, et al. A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer[J]. NPJ Precis Oncol, 2019, 3:25.
[15] FRAUNHOFFER N, HAMMEL P, CONROY T, et al. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma[J]. Ann Oncol, 2024, 35(9):780-791.
[16] CHAN-SENG-YUE M, KIM J C, WILSON G W, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution[J]. Nat Genet, 2020, 52(4):231-240.
[17] GOLAN T, HAMMEL P, RENI M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer[J]. N Engl J Med, 2019, 381(4):317-327.
[18] MAHADEVAN K K, MCANDREWS K M, LEBLEU V S, et al. KRASG12Dinhibition reprograms the microenvironment of early and advancedpancreatic cancer to promote FAS-mediated killing by CD8+ T cells[J]. Cancer Cell, 2023, 41:1606-620,e8.
[19] WASKO U N, JIANG J, DALTON T C, et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer[J]. Nature, 2024, 629(8013):927-936.
[20] SINGHAL A, LI B T, O’REILLY E M. Targeting KRAS in cancer[J]. Nat Med, 2024, 30(4):969-983.
[21] TEMPERO M A, MALAFA M P, AL-HAWARY M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(4):439-457.
[22] KRISHNAN S, CHADHA A S, SUH Y, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation[J]. Int J Radiat Oncol Biol Phys, 2016, 94(4):755-765.
[23] ABI JAOUDE J, THUNSHELLE C P, KOUZY R, et al. Stereotactic versus conventional radiation therapy for patients with pancreatic cancer in the modern era[J]. Adv Radiat Oncol, 2021, 6(6):100763.
[24] HAMMEL P, HUGUET F, VAN LAETHEM J L, et al. Effect of chemoradiotherapy vs. chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial[J]. JAMA, 2016, 315(17):1844-1853.
[25] RAINER FIETKAU, MICHAEL GHADIMI, UWE A WITTEL, et al. Randomized phase Ⅲ trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial[J]. J Clin Oncol, 2022, 40(16):4008.
[26] TORGESON A, LLOYD S, BOOTHE D, et al. Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer[J]. Cancer, 2017, 123(19):3816-3824.
[27] FAISAL F, TSAI H L, BLACKFORD A, et al. Longer course of induction chemotherapy followed by chemoradiation favors better survival outcomes for patients with locally advanced pancreatic cancer[J]. Am J Clin Oncol, 2016, 39(1):18-26.
[28] SAIF A, VERBUS E, ERICKSON B, et al. A randomized, phase Ⅱ, clinical trial of preoperative fractionated radiation therapy versus stereotactic body radiation therapy for resectable, borderline resectable, or locally advanced type a pancreatic adenocarcinoma[J]. Ann Surg Oncol, 2023, 30(2):688-690.
[29] BARCELLINI A, MOLINELLI S, VANOLI A, et al. Preoperative chemo-CIRT in Re/BRe pancreatic cancer: insights from a multicenter prospective phase Ⅱ clinical study (NCT03822936)[J]. Tumori, 2024, 110(6):470-474.
[30] SUGIURA T, TOYAMA H, FUKUTOMI A, et al. Randomized phase Ⅱ trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04)[J]. J Hepatobiliary Pancreat Sci, 2023, 30(11):1249-1260.
Options
Outlines

/

〈 〉